PT-141 peptide (bremelanotide) is an FDA-approved injection for low sexual desire in premenopausal women. Learn how it works, dosing, side effects, and risks.
PT-141 peptide — also known as bremelanotide — is a synthetic melanocortin receptor agonist that the U.S. Food and Drug Administration approved in 2019 under the brand name Vyleesi for hypoactive sexual desire disorder (HSDD) in premenopausal women. It is given as a subcutaneous injection into the abdomen or thigh at least 45 minutes before anticipated sexual activity. PT-141 is not a hormone, not a vasodilator like sildenafil, and not approved for men or for general libido enhancement.
What Is the PT-141 Peptide?
PT-141 started as a research compound derived from melanotan II, a peptide that was originally studied for tanning effects. Chemically, it is a cyclic heptapeptide analog of alpha-melanocyte-stimulating hormone (α-MSH).
During early trials, participants reported increased sexual desire as an unexpected side effect, and that observation shifted the molecule's development toward sexual medicine. Some people search for it as "peptide 141," and both spellings refer to the same molecule.
In the United States, PT-141 is legally available only as a prescription auto-injector. It is also widely sold as a lyophilized powder labeled "for research use only," which is a different product category with no quality or dosing guarantees.
How PT-141 Works in the Body
Bremelanotide activates melanocortin receptors, particularly MC4R, in the central nervous system. That activation appears to influence dopamine pathways tied to desire and arousal rather than blood flow to the genitals.
This mechanism is different from PDE5 inhibitors such as sildenafil or tadalafil, which act on vascular smooth muscle. Because PT-141 acts centrally, researchers measure its effects through changes in desire and in the number of satisfying sexual events — not through erection hardness alone.
In the phase 3 RECONNECT trials, premenopausal women with HSDD using bremelanotide reported a modest increase in satisfying sexual events compared with placebo, roughly 0.3 additional events per month, plus a small improvement in desire scores. The benefit is real but modest, which is why many clinicians treat it as one option among several rather than a first-line therapy.
FDA Approval Status and Legal Landscape
Vyleesi is the only FDA-approved bremelanotide product. Its approved indication is HSDD in premenopausal women, and there is no approved version of PT-141 for men, for postmenopausal women, or for recreational use.
PT-141 sold online as a research chemical or "peptide 141" is not FDA-approved, is not required to be made under Good Manufacturing Practice standards, and may contain impurities or incorrect concentrations. Importing or buying prescription drugs from unverified sources is illegal in the United States and carries real safety risk.
PT-141 is a prescription medication in the United States, and self-dosing with research-grade powder is not a substitute for medical supervision.
Dosing and Product Forms Compared
Product form matters as much as dose. The table below summarizes how the main versions of PT-141 differ in regulatory status and typical use.
| Form | FDA status | Typical dose | Notes |
|---|---|---|---|
| Vyleesi auto-injector | Approved (HSDD, premenopausal women) | 1.75 mg subcutaneously, at least 45 minutes before activity | Maximum 1 dose per 24 hours and no more than 8 doses per month |
| Compounded subcutaneous PT-141 | Not approved | Variable, often 1–2 mg | Requires a prescription; pharmacy quality varies |
| Nasal spray PT-141 | Not approved | Variable | The original nasal formulation was discontinued after blood pressure increases |
| "Research chemical" powder | Not approved for human use | Not established | Sold for laboratory research only; no clinical dosing guidance |
Side Effects and Safety Considerations
Nausea is the most commonly reported side effect, occurring in roughly 40% of trial participants. Flushing, headache, vomiting, and injection-site reactions are also common.
Bremelanotide can cause a temporary rise in blood pressure and a small drop in heart rate after injection. People with uncontrolled hypertension or known cardiovascular disease should not use it, and it is contraindicated during pregnancy.
Repeated use has been linked to focal hyperpigmentation — dark patches on the face, gums, or genital area — which may not fully fade after the drug is stopped. PT-141 can also interact with other medications, including some antidepressants and antihypertensives.
Anyone considering the PT-141 peptide should review cardiovascular history, current prescriptions, and pregnancy status with a healthcare professional before using it.
How PT-141 Compares With Other Peptides
PT-141 sits inside a large and fast-growing category of research peptides, and it is easy to confuse it with compounds studied for completely different purposes. None of the items below are interchangeable with PT-141.
- aod9604 peptide — a fragment of human growth hormone studied for fat metabolism, not desire.
- bpc-157 peptide for inflammation — investigated in tissue-repair and inflammation models, with no FDA approval for human use.
- glucagon-like peptide-1 supplement and gastric inhibitory peptide — metabolic gut hormones that influence appetite and blood sugar and are frequently discussed alongside GLP-1 weight-loss drugs.
- peptide for hair growth — a cosmeceutical category sold in serums and shampoos, with far weaker evidence than prescription drugs.
One practical takeaway: PT-141 is a regulated central-nervous-system drug, while most peptides sold online are unapproved research chemicals. Treating them as a single bucket is a common and costly mistake.
What to Know Before Considering PT-141
If you are weighing PT-141 as an option, keep these points in mind:
- PT-141 is a prescription drug in the US, and Vyleesi is the only approved product.
- It is approved for premenopausal women with HSDD, not for men or general sexual enhancement.
- Its average benefit in clinical trials was modest, not dramatic.
- Nausea and short-term blood pressure changes are the primary safety concerns.
- People with cardiovascular disease or uncontrolled hypertension should avoid it.
Low sexual desire often has multiple drivers, including medications, hormonal changes, mental health, sleep, and relationship factors. A clinician can help sort out which of those matter most, and whether a prescription like bremelanotide is a reasonable next step.
PT-141 peptide is a prescription medication, not a supplement, and it is not FDA-approved for men or for general sexual enhancement.
Frequently Asked Questions
Is PT-141 FDA-approved?
Yes, but only in one specific form. Bremelanotide injection, sold as Vyleesi, was approved by the FDA in 2019 for hypoactive sexual desire disorder in premenopausal women. PT-141 powder or nasal sprays sold online as research chemicals are not FDA-approved for human use.
Does PT-141 work for men?
There is no FDA-approved PT-141 product for men. Small studies have tested bremelanotide in men with erectile dysfunction, but results were mixed and the drug is not approved for that use. Men should ask a healthcare professional about approved treatment options first.
What are the side effects of PT-141 peptide?
Nausea is the most common side effect, reported by roughly 40% of participants in clinical trials. Flushing, headache, vomiting, injection-site reactions, and temporary increases in blood pressure are also reported. Repeated use has been associated with focal hyperpigmentation that may not fully fade.
This page provides educational research information and does not replace medical advice, diagnosis, or treatment.